Posters

Time course of changes in contrast sensitivity following intravitreal ranibizumab injection for branch retinal vein occlusion

Poster Details

First Author: Y.Sugiura JAPAN

Co Author(s):    F. Okamoto   S. Morikawa   Y. Okamoto   T. Oshika                    

Abstract Details



Purpose:

To evaluate contrast sensitivity in patients with branch retinal vein occlusion (BRVO) following intravitreal ranibizumab injection (IVR), and to investigate the relationship between contrast sensitivity and retinal microstructure.

Setting:

Prospective, consecutive, interventional case series.

Methods:

We included 23 eyes of 23 patients with macular edema caused by BRVO who were followed up for 6 months after initial treatment. All patients were treatment naïve with no history of treatment with intravitreal anti-VEGF injection, intraocular corticosteroids, grid or panretinal photocoagulation, or pars plana vitrectomy. We measured best-corrected visual acuity (BCVA), letter contrast sensitivity (LC) and 10% low contrast visual acuity (LCVA). The retinal microstructure was evaluated with optical coherence tomography (OCT). All tests were performed before and 1, 2, 3, 4, 5, and 6 months after treatment. Based on OCT images, we assessed central retinal thickness (CRT), presence of serous retinal detachment, and status of the external limiting membrane and ellipsoid zone.

Results:

IVR treatment significantly improved contrast sensitivity (LC: P < 0.0001, LCVA: P < 0.005) as well as BCVA (P < 0.005) and CRT (P < 0.0001). Post-treatment BCVA and contrast sensitivity showed no significant correlations with pre- and post-treatment OCT parameters. In patients with good baseline BCVA (logMAR < 0.2), although BCVA did not change, LC and LCVA showed significant improvements (P < 0.05, P < 0.01) by IVR. In patients with poor improvement in BCVA (pre-post logMAR BCVA < 0.2), LC and LCVA also showed significant improvements (P < 0.001, P < 0.005).

Conclusions:

IVR treatment for BRVO significantly improved not only BCVA but also contrast sensitivity. Even in patients with good baseline BCVA or poor improvement in BCVA, contrast sensitivity improved by IVR.

Back to previous
EURETINA, Temple House, Temple Road, Blackrock, Co Dublin. | Phone: 00353 1 2100092 | Fax: 00353 1 2091112 | Email: euretina@euretina.org

Privacy policyHotel Terms and Conditions Cancellation policy